Trial Condition(s):

Cancer

A clinical study of anetumab ravtansine in adults with solid tumors who have been treated in previous Bayer-sponsored anetumab ravtansine studies

Bayer Identifier:

20322

ClinicalTrials.gov Identifier:

NCT03926143

EudraCT Number:

2019-000061-20

Study Completed

Trial Purpose

The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.

Inclusion Criteria
- Participants ongoing in an applicable Bayer-sponsored anetumab ravtansine parent study at the time of its planned study closure.
                - For on-treatment participants: participant is eligible to receive the next dose of study intervention per the parent study protocol.
Exclusion Criteria
- For on-treatment participants: a positive serum pregnancy test.
                - For on-treatment participants: use of one or more of the prohibited medications listed in the respective parent study protocol.
                - Participants who are receiving standard-of-care agent(s) but not anetumab ravtansine in the parent study, and are able to receive standard-of-care agent outside of the clinical study.

Trial Summary

Enrollment Goal
9
Trial Dates
black-arrow
Phase
2
Could I receive a placebo?
No
Products
Anetumab ravtansine (BAY94-9343)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Szpital Wojewodzki W Szczecinie Zdunowie

Szczecin, Poland, 70-891

Status
Completed
 
Locations

Hôpital de la Timone - Marseille

Marseille, France, 13385

Status
Completed
 
Locations

Sarah Cannon Cancer Center

Nashville, United States, 37203

Status
Completed
 
Locations

Mary Crowley Medical Research Center

Dallas, United States, 75230

Status
Completed
 
Locations

National Cancer Institute - Maryland

Bethesda, United States, 20892

Status
Completed
 
Locations

University of Chicago

Chicago, United States, 60637

Status
Completed
 
Locations

ASST Grande Ospedale Metropolitano Niguarda

Milano, Italy, 20162

Status
Completed
 

Trial Design